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The evidence continues to mount that Chronic Lyme Disease (CLD) exists and must be addressed by the medical community
if solutions are to be found. Four National Institutes of Health (NIH) trials validated the existence and severity of CLD. Despite
the evidence, there are physicians who continue to deny the existence and severity of CLD, which can hinder eﬀorts to ﬁnd a
solution. Recognizing CLD could facilitate eﬀorts to avoid diagnostic delays of two years and durations of illness of 4.7 to 9 years
described in the NIH trials. The risk to society of emerging antibiotic-resistant organisms should be weighed against the societal
risks associated with failing to treat an emerging population saddled with CLD. The mixed long-term outcome in children could
also be examined. Once we accept the evidence that CLD exists, the medical community should be able to ﬁnd solutions. Medical
professionals should be encouraged to examine whether: (1) innovative treatments for early LD might prevent CLD, (2) early
diagnosis of CLD might result in better treatment outcomes, and (3) more eﬀective treatment regimens can be developed for CLD
patients who have had prolonged illness and an associated poor quality of life.
The evidence continues to mount that Chronic Lyme
Disease (CLD) exists and must be addressed by the med-
ical community if solutions are to be found. Thirty-four
percent of a population-based, retrospective cohort study
in Massachusetts were found to have arthritis or recurrent
arthralgias, neurocognitive impairment, and neuropathy or
myelopathy, a mean of 6 years after treatment for Lyme
disease (LD) [1]. Sixty-two percent of a cohort of 215
consecutively treated LD patients in Westchester County
were found to have arthralgias, arthritis, and cardiac or
neurologic involvement with or without fatigue a mean
of 3.2 years after treatment [2]. Klempner trials’ subjects
presenting with “well-documented, previously treated Lyme
disease...had persistent musculoskeletal pain, neurocogni-
tive symptoms, or dysesthesia, often associated with fatigue”
and were ill during a mean of 4.7 years after onset [3].
Fallontrialsubjectspresentingwith“well-documentedLyme
disease, with at least 3 weeks of prior IV antibiotics,
current positive IgG Western blot, and objective memory
impairment,” were ill during a mean of 9 years after onset
[4]. Krupp LD subjects presented with “persistent severe
fatigue at least 6 or more months after antibiotic therapy”
[5].
There is also evidence that symptoms of CLD can
be severe [4–8]. The Klempner trials described the qual-
ity of life for patients with posttreatment chronic Lyme
disease (PTLD) as being equivalent to that of patients
with congestive heart failure or osteoarthritis, and their
physical impairment was “more than 0.5 SD greater than
the impairment observed in patients with type 2 diabetes or
a recent myocardial infarction” [3]. Fallon et al. described
painreportedbypatientswithLymeencephalopathyasbeing
“...similar to those of postsurgery patients”, and their fatigue
“was similar to that of patients with multiple sclerosis.”
Limitations in physical functioning on a quality of life scale
were “comparable with those of patients with congestive
heart failure” [4].
Despite the above documented evidence, the 2006 Infec-
tious Diseases Society of America (IDSA) LD treatment
guideline panel questioned the existence of CLD [9]. The
IDSA panel concluded, “Considerable confusion and con-
troversy exist over the frequency and cause of this process
and even over its existence” [9]. The IDSA panel referred to
chronicmanifestationsofLDasPost-Lymediseasesyndrome
(PLDS), PTLD and CLD. There are shortcomings for each
term. The PLDS nomenclature implies that an active LD
has been successfully treated, that any remaining symptoms2 Interdisciplinary Perspectives on Infectious Diseases
are merely harmless vestiges of previous illness, and that the
patient has been cured. The term PTLD merely implies that
LD has been treated with antibiotics for 10 to 30 days. The
CLD nomenclature implies that chronic manifestations of
LD are present with or without evidence of active infection
that cannot be reasonably explained by another illness.
There is no objective way to rule out an active infection.
Lab tests that can be very helpful in conﬁrming a clinical
diagnosis of Lyme disease (such as the ELISA and Western
blot tests) are not useful in determining whether the infec-
tion has been adequately treated. Common LD symptoms
such as Bell’s palsy, erythema migrans rash, meningitis,
arthritis, or heart block, which are included in the current
surveillance deﬁnitions, can be useful in “ruling in” Lyme
disease, but the absence or disappearance of these symptoms
cannot “rule out” an ongoing infection. A population-based,
retrospectivecohortstudyof individuals witha historyof LD
revealed that they were signiﬁcantly more likely to have joint
pain,memoryimpairment,andpoorfunctionalstatusdueto
pain than personswithoutahistory ofLD,eventhough there
were no signs of objective ﬁndings on physical examination
or neurocognitive testing [10]. Two recent mouse studies
revealed that spirochetes persist despite antibiotic therapy
and that standard diagnostic tests are not able to detect their
presence [11, 12]. In sum, there are no clinical or laboratory
markers that identify the eradication of the pathogen.
The IDSA panel also questioned the severity of CLD
symptoms. The panel dismissed LD symptoms that persisted
or recurred after their recommended, short-term course of
treatment, stating that they were: “more related to the aches
and pains of daily living rather than to either Lyme disease
or a tickborne coinfection” [13]. The panel came to this
conclusion despite four NIH retreatment trials that validated
the severity of symptoms on 22 standardized measures of
fatigue, pain, role function, psychopathology, cognition, and
quality of life (QOL) [9].
Denying the existence and severity of CLD will continue
to hinder the eﬀorts to ﬁnd a solution. Even in a prospective
trial of LD, 10 to 16% of patients treated at the time of an
erythema migrans rash remained symptomatic a mean of 30
months after treatment; the results varied depending on the
duration of antibiotics treatment [14]. The actual failure rate
in this prospective at 30 months is uncertain, given that 38%
of the subjects were not evaluable due to poor adherence,
receipt of intercurrent antibiotics, or development of a
second episode of erythema migrans [14]. Patients infected
with many other kinds of common bacteria—such as those
that cause tuberculosis, bronchitis, or UTIs—can experience
relapses after an initial course of antibiotic treatment fails
or proves inadequate. Doctors routinely retreat patients who
relapse in order to achieve a cure and prevent chronic
symptoms.WhyshouldpatientswithLymediseasebetreated
diﬀerently?
T h et r e a t m e n tf a i l u r er a t e sc o u l db ee x a c e r b a t e db y
diagnostic delays. Feder described treatment delays of six
weeks in LD patients initially misdiagnosed with cellulitis
[15]. In his trial, Fallon noted treatment delays averaging
2y e a r s[ 4] without examining the causes of the delay. In
my own practice, 32% of a consecutive case series of LD
cases (conﬁrmed by an ELISA and 5 or more positive bands
on a IgG Western blot) had an average treatment delay
of 1.8 years. [16] Of these, 60% conformed to Centers
for Disease Control and Prevention (CDC) epidemiological
criteria, presenting with a rash, Bell’s palsy, or arthritis, yet,
still had a diagnostic delay [16]. Patients in this case series
were signiﬁcantly more likely to fail their initial antibiotic
treatment if they had delayed treatment [16]. Vrethem et
al. concluded that patients treated because of neurological
symptoms of LD were much more likely to present with
persistent neuropsychiatric symptoms (headache, attention
problems, memory diﬃculties, and depression) three years
after treatment than a control group with erythema migrans
(50% versus 16%, P<. 0001) [17].
The diagnostic delays could reﬂect the failure to consider
CLDinthediﬀerentialdiagnosisofchronicmanifestationsof
LD. Steere did not include CLD in the diﬀerential diagnosis
of patients seen in his university-based clinic. Instead, Steere
diagnosed three-quarters of patients with “ﬁbromyalgia”
or “chronic fatigue syndrome” [18]. Similarly, Reid et al.
did not include CLD as a diagnosis in their university LD
clinic. Instead, he diagnosed these patients with “arthralgia-
myalgia syndrome,” primary depression, asymptomatic deer
tick bites, osteoarthritis, and bursitis [16]. Hassett et al.
diagnosed PTLD in patients with a history of objective
evidence of LD, but withheld it from patients who lacked
such a history. Instead, this group was diagnosed with
“Chronic Multisymptom Illness (MUI) [19]. Their case
deﬁnition for Chronic Multisymptom Illness was: “ [having]
at least one or more chronic symptoms from at least 2 of 3
categories of symptoms including musculoskeletal, fatigue,
and mood cognition” that includes ﬁbromyalgia, chronic
fatigue syndrome, and Gulf War syndrome [19].
The risks to the individual and society of CLD have not
been adequately considered [20]. As a group, CLD subjects
in the four NIH trials had a 4% risk of a serious adverse
event in the antibiotic treatment arms [4–6]. Yet, this risk
has not been weighed against the risk CLD patients face
if burdened with a long-term debilitating illness. The risk
to society of emerging resistant organisms also has not
been weighed against the societal risks associated with an
emerging population saddled with CLD [8].
The economic burden of CLD has yet to be addressed.
The mean cost estimate of CLD per patient in the US, of
$16,199 per annum in 2002 dollars [8], reﬂects the toll on
human health and cost to society. The annual per-patient
cost of CLD is substantially higher than the cost for other
common chronic illnesses: $10,911 for ﬁbromyalgia [21], $
10,716 for rheumatoid arthritis [21], and $13,094 for lupus
[22]. Eighty-eight percent of the cost ($14,327) of Lyme
disease consisted of indirect medical cost, nonmedical cost,
and productivity losses. Cutting medical cost would save, at
most, only 12% or $1,872 per annum. In 2002, the annual
economic cost of LD in the US, based on the 23,000 cases
reported to the CDC that year, was estimated to be $203
million [8]. Considering that the actual number of LD cases
is believed to be 10 times higher than the number of cases
reported to the CDC, the actual annual cost could be $2
billion [23, 24].Interdisciplinary Perspectives on Infectious Diseases 3
TheburdenofCLDisalsoreﬂectedintestimonygivenby
Connecticut’s chief epidemiologist before the state’s Public
Health Department in 2004: “...roughly one percent of the
entire population or probably 34,000 people are getting a
diagnosis of Lyme Disease in Connecticut each year...20 to
25 percent of all families [in Connecticut] have had at least
one person diagnosed with Lyme Disease ever and...three to
ﬁve percent of all families have had someone diagnosed with
Lyme Disease in the past year” [24].
No additional antibiotic trials have been planned for
CLD patients despite the limitations of the Klempner
and Fallon trials. Klempners’ trials were limited by: (1)
uncertainty over whether the initial antibiotic treatment
was eﬀective, (2) ongoing illness despite a mean of three
previous treatments, (3) long onsets of illness averaging 4.7
years, (4) the poor quality of life of the subjects, and (5)
small, underpowered sample sizes of 51 and 78 subjects
[25]. The Fallon trial had similar limitations including: (1)
uncertainty over whether the initial antibiotic treatment was
eﬀective, (2) treatment delays averaging two years, (3) onsets
of illness averaging 9 years, (4) the severe pain, fatigue,
psychopathology, and poor QOL of subjects, and (5) a small
underpowered sample size of 37 subjects. The IDSA panel
did not suggest any further clinical trials to address these
limitations. In an editorial titled “Enough is Enough”, which
was published as a commentary on Fallon’s trial, Halperin,
anIDSApanelmember,actuallyadvisedagainstfurthertrials
[26].
There is also an urgent need to address the mixed long-
term outcome in children. Eleven percent of children with
facial nerve palsy had persistent facial nerve palsy causing
dysfunctional and cosmetic problems at 6-month followup
[27]. Fourteen percent of 86 children had neurocognitive
symptoms associated with or after classic manifestations of
Lyme disease on followup [28]. Five of these children devel-
oped “behavioral changes, forgetfulness, declining school
performance, headache or fatigue and in two cases a partial
complex seizure disorder” [28]. Children with prior cranial
nerve palsy have signiﬁcantly more behavioral changes (16%
vs. 2%), arthralgias and myalgias (21% vs. 5%), and memory
problems (8% vs. 1%) an average of 4 years after treatment
compared to controls [29].
Once we accept the evidence that CLD exists, the medical
community should be able to ﬁnd solutions. Professionals
should be encouraged to examine whether: (1) innovative
treatments for early LD might prevent CLD, (2) early
diagnosis of CLD might result in better treatment outcomes,
and (3) more eﬀective regimens can be developed for CLD
patients who have had prolonged illness and an associated
poor quality of life.
References
[1] N. A. Shadick, C. B. Phillips, E. L. Logigian, et al., “The long-
term clinical outcomes of Lyme disease. A population-based
retrospective cohort study,” Annals of Internal Medicine, vol.
121, no. 8, pp. 560–567, 1994.
[2] E. S. Asch, D. I. Bujak, M. Weiss, M. G. E. Peterson, and
A. Weinstein, “Lyme disease: an infectious and postinfectious
syndrome,” Journal of Rheumatology, vol. 21, no. 3, pp. 454–
461, 1994.
[3] M.S.Klempner ,L.T .H u,J .E vans,etal.,“T w oc ontr olledtrials
of antibiotic treatment in patients with persistent symptoms
and a history of Lyme disease,” New England Journal of
Medicine, vol. 345, no. 2, pp. 85–92, 2001.
[4] B. A. Fallon, J. G. Keilp, K. M. Corbera, et al., “A randomized,
placebo-controlled trial of repeated IV antibiotic therapy for
Lyme encephalopathy,” Neurology, vol. 70, no. 13, pp. 992–
1003, 2008.
[ 5 ]L .B .K r u p p ,L .G .H y m a n ,R .G r i m s o n ,e ta l . ,“ S t u d ya n d
treatment of post Lyme disease (STOP-LD): a randomized
double masked clinical trial,” Neurology, vol. 60, no. 12, pp.
1923–1930, 2003.
[6] M. S. Klempner, “Controlled trials of antibiotic treatment in
patients with post-treatment chronic Lyme disease,” Vector
Borne and Zoonotic Diseases, vol. 2, no. 4, pp. 255–263, 2002.
[7] D.J.Cameron,“Clinicaltrialsvalidatetheseverityofpersistent
Lyme disease symptoms,” Medical Hypotheses,v o l .7 2 ,n o .2 ,
pp. 153–156, 2009.
[ 8 ]X .Z h a n g ,M .I .M e l t z e r ,C .A .P e n a ,A .B .H o p k i n s ,L .W r o t h ,
and A. D. Fix, “Economic impact of Lyme disease,” Emerging
Infectious Diseases, vol. 12, no. 4, pp. 653–660, 2006.
[ 9 ] G .P .W o r m s e r ,R .J .D a t t w y l e r ,E .D .S h a p i r o ,e ta l . ,
“The clinical assessments treatment, and prevention of Lyme
disease, human granulocytic anaplasmosis, and babesiosis:
clinical practice guidelines by the Infectious Diseases Society
of America,” Clinical Infectious Diseases,v o l .4 3 ,n o .9 ,p p .
1089–1134, 2006.
[10] N. A. Shadick, C. B. Phillips, O. Sangha, et al., “Muscu-
loskeletalandneurologicoutcomesinpatientswithpreviously
treatedLymedisease,”AnnalsofInternalMedicine,vol.131,no.
12, pp. 919–926, 1999.
[11] E. Hodzic, S. Feng, K. Holden, K. J. Freet, and S. W. Barthold,
“Persistence of Borrelia burgdorferi following antibiotic treat-
ment in mice,” Antimicrobial Agents and Chemotherapy, vol.
52, no. 5, pp. 1728–1736, 2008.
[12] H. Yrj¨ an¨ ainen, J. Hyt¨ onen, K.-O. S¨ oderstr¨ om, J. Oksi, K.
Hartiala, and M. K. Viljanen, “Persistent joint swelling and
borrelia-speciﬁc antibodies in Borrelia garinii-infected mice
after eradication of vegetative spirochetes with antibiotic
treatment,” Microbes and Infection, vol. 8, no. 8, pp. 2044–
2051, 2006.
[13] J. J. Halperin, E. D. Shapiro, E. Logigian, et al., “Prac-
tice parameter: treatment of nervous system Lyme disease
(an evidence-based review): report of the quality standards
subcommittee of the American Academy of Neurology,”
Neurology, vol. 69, no. 1, pp. 91–102, 2007.
[14] G. P. Wormser, R. Ramanathan, J. Nowakowski, et al.,
“Duration of antibiotic therapy for early Lyme disease: a
randomized,double-blind,placebo-controlledtrial,”Annalsof
Internal Medicine, vol. 138, no. 9, pp. 697–704, 2003.
[15] H. M. Feder Jr. and D. L. Whitaker, “Misdiagnosis of erythema
migrans,”AmericanJournalofMedicine,vol.99,no.4,pp.412–
419, 1995.
[16] M. C. Reid, R. T. Schoen, J. Evans, J. C. Rosenberg, and R. I.
Horwitz, “The consequences of overdiagnosis and overtreat-
ment of Lyme disease: an observational study,” Annals of
Internal Medicine, vol. 128, no. 5, pp. 354–362, 1998.
[17] M. Vrethem, L. Hellblom, M. Widlund, et al., “Chronic
symptoms are common in patients with neuroborreliosis—a
questionnaire follow-up study,” Acta Neurologica Scandinav-
ica, vol. 106, no. 4, pp. 205–208, 2002.4 Interdisciplinary Perspectives on Infectious Diseases
[18] A. C. Steere, E. Taylor, G. L. McHugh, and E. L. Logigian,
“The overdiagnosis of Lyme disease,” Journal of the American
Medical Association, vol. 269, no. 14, pp. 1812–1816, 1993.
[19] A. L. Hassett, D. C. Radvanski, S. Buyske, S. V. Savage, and
L. H. Sigal, “Psychiatric comorbidity and other psychological
factors in patients with “chronic Lyme disease”,” American
Journal of Medicine, vol. 122, no. 9, pp. 843–850, 2009.
[20] D. J. Cameron, “Insuﬃcient evidence to deny antibiotic treat-
ment to chronic Lyme disease patients,” Medical Hypotheses,
vol. 72, no. 6, pp. 688–691, 2009.
[21] S. Silverman, E. M. Dukes, S. S. Johnston, N. A. Brandenburg,
A. Sadosky, and D. M. Huse, “The economic burden of
ﬁbromyalgia: comparative analysis with rheumatoid arthritis,”
Current Medical Research and Opinion, vol. 25, no. 4, pp. 829–
840, 2009.
[ 2 2 ]A .E .C l a r k e ,J .M .E s d a i l e ,D .A .B l o c h ,D .L a c a i l l e ,D .S .
Danoﬀ, and J. F. Fries, “A Canadian study of the total medical
costs for patients with systemic lupus erythematosus and the
predictors of costs,” Arthritis and Rheumatism, vol. 36, no. 11,
pp. 1548–1559, 1993.
[23] G. D. Ebel, E. N. Campbell, H. K. Goethert, A. Spielman, and
S. R. Telford III, “Enzootic transmission of deer tick virus
in new England and Wisconsin sites,” American Journal of
Tropical Medicine and Hygiene, vol. 63, no. 1-2, pp. 36–42,
2000.
[24] http://www.ct.gov/ag/lib/ag/health/0129lyme.pdf, p. 290,2008.
[25] D. J. Cameron, “Generalizability in two clinical trials of Lyme
disease,” Epidemiologic Perspectives and Innovations, vol. 3,
article 12, 2006.
[26] J. J. Halperin, “Prolonged Lyme disease treatment: enough is
enough,” Neurology, vol. 70, no. 13, pp. 986–987, 2008.
[27] B. H. Skogman, S. Croner, M. Nordwall, M. Eknefelt, J.
Ernerudh, and P. Forsberg, “Lyme neuroborreliosis in chil-
dren: a prospective study of clinical features, prognosis, and
outcome,” Pediatric Infectious Disease Journal, vol. 27, no. 12,
pp. 1089–1094, 2008.
[28] B. J. Bloom, P. M. Wyckoﬀ, H. C. Meissner, and A. C.
Steere, “Neurocognitive abnormalities in children after classic
manifestations of Lyme disease,” Pediatric Infectious Disease
Journal, vol. 17, no. 3, pp. 189–196, 1998.
[29] M. V´ azquez, S. S. Sparrow, and E. D. Shapiro, “Long-term
neuropsychologic and health outcomes of children with facial
nerve palsy attributable to Lyme disease,” Pediatrics, vol. 112,
no. 2, pp. e93–e97, 2003.